Please try another search
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Laura J. Hamill | 57 | 2019 | Independent Director |
John P. Schmid | 59 | 2015 | Independent Director |
Hollings C. Renton | 75 | 2015 | Lead Independent Director |
Dennis M. Fenton | 70 | 2018 | Independent Director |
Daniel R. Faga | 43 | 2021 | President, CEO & Director |
Magda Marquet | 65 | 2021 | Independent Director |
John A. Orwin | 59 | 2023 | Independent Chairman of the Board |
John G. Monroe | - | - | Member of Scientific Advisory Board |
Christopher Hunter | - | - | Member of Scientific Advisory Board |
Luisa Salter-Cid | 60 | - | Member of Scientific Advisory Board |
Rita I. Jain | 61 | 2023 | Independent Director |
J. Anthony Ware | 70 | 2017 | Independent Director |
Oleg Nodelman | 47 | 2021 | Independent Director |
Dolca Thomas | 53 | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review